Brief: Amarin And Csl Seqirus Announce Exclusive License And Distribution Agreement To Commercialize Vazkepa In Australia And New Zealand
28/02/2023 13:20
Feb 28 (Reuters) - Amarin Corporation PLC AMRN.O :
* AMARIN AND CSL SEQIRUS ANNOUNCE EXCLUSIVE LICENSE AND
DISTRIBUTION AGREEMENT TO COMMERCIALIZE VAZKEPA® (ICOSAPENT
ETHYL)IN AUSTRALIA AND NEW ZEALAND
* UNDER AGREEMENT, CSL SEQIRUS WILL IN-LICENSE VAZKEPA FROM
CO
* IN DEAL,CSL SEQIRUS RESPONSIBLE FOR MARKET
ACCESS,REIMBURSEMENT
EFFORTS,DISTRIBUTION,COMMERCIAL PROMOTION FOR VAZKEPA ACROSS
AUSTRALIA,NEW ZEALAND
* AMARIN WILL BE RESPONSIBLE FOR SUPPLYING FINISHED PRODUCT
TO CSL
SEQIRUS AT A PROFITABLE TRANSFER PRICE PAID TO AMARIN
Source text for Eikon: ID:nGNE5Wq3Nc
Further company coverage: AMRN.O
Recent news on Amarin
See all newsAmarin Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Ireland's Amarin Q2 revenue falls on lower licensing payments
Amarin Corporation PLC expected to post a loss of 1 cent a share - Earnings Preview
US Supreme Court backs generic drugmaker in 'skinny label' patent case (updated)
US Supreme Court backs generic drugmaker in 'skinny label' patent case